Description
Overcoming Obstacles in Drug Discovery and Development uses real-world case studies to illustrate how critical thinking and problem solving skills are applied in the discovery and development of drugs. It also shows how developing critical thinking to overcome issues plays an essential role in the process. Modern drug discovery and development is a highly complex undertaking that requires scientific and professional expertise to be successful. After the identification of a molecular entity for treating a medical condition, challenges inevitably arise during the subsequent development to understand and characterize the biological profile; feedback from scientists is used to fine-tune the molecular entity to obtain an effective and safe product. In this process, the discovery team may identify unexpected safety issues and new medical disorders for treatment by the molecular entity. Invariably inherent in this complex undertaking are miscues, mistakes, and unexpected problems that can derail development and throw timetables into disarray, potentially leading to failure in the development of a medically useful drug. Addressing critical unexpected problems during development often requires scientists to utilize critical thinking and imaginative problem-solving skills. Overcoming Obstacles in Drug Discovery and Development will be essential to young scientists to help learn the skills to successfully face challenges, learn from mistakes, and further develop critical thinking skills. It will also be beneficial to experienced researchers who can learn from the case studies of successful and unsuccessful drug development.
About the Author
Dr. Kan He holds more than 10 U.S. and international patents on new chemical entities and biotechnologies and is the author of more than 60 published scientific papers. In addition to contributing to the discovery and development of numerous successful prescription drugs currently on the market, as well as multiple preclinical and clinical development candidates, Dr. He made significant contributions to the discovery and development of the oral anticoagulant Eliquis (R) (Apixaban). Dr. He cofounded and currently serves as the General Manager of the innovative biotech service company Biotranex, now a wholly owned subsidiary of Frontage Laboratories, Inc. Dr. He has also held numerous scientific and managerial positions at Bristol-Myers Squib, Dupont Pharmaceuticals, and Pfizer, and cofounded and served as President of Princeton Drug Discovery Inc, Eternity Bioscience, and UniTris Biopharma. Dr. Paul Hollenberg is a Professor Emeritus of Pharmacology at the University of Michigan Medical School. He was on the faculty at Northwestern University Medical School, Wayne State University School of Medicine (Chair of Pharmacology), and then at the University of Michigan Medical School where he was Chair for more than 20 years. He cofounded Chemical Research in Toxicology in 1988 and has served as an Associate Editor and then Review Editor since that time. He was elected a Fellow of the American Chemical Society (2010), the American Association for the Advancement of Science (2012), and the American Society of Pharmacology and Therapeutics (2019). He has received several awards including the Scientific Achievement Award from the International Society for the Study of Xenobiotics in 2011 and the Founders Award from the Division of Chemical Toxicology of the American Chemical Society in 2014. He has published more than 200 peer-reviewed papers and received more than $29 million in NIH funding as a PI or Co-PI. Dr. Wienkers is currently the Principal Scientist of Wienkers Consulting, LLC. Prior to this, Larry was Vice President and Global Head of the department of Pharmacokinetics and Drug Metabolism at Amgen retiring in 2018. Before moving to Amgen, Dr. Wienkers held scientific and leadership positions in several companies (Upjohn, Pharmacia, and Pfizer) and worked across multiple drug modalities, resulting in clinical and preclinical candidates, with 30+ IND submissions and 10+ NDA submissions. He is an American Association of Pharmaceutical Scientists (AAPS) Fellow (2012), was the recipient of the University of Washington, School of Pharmacy Distinguished Alumni Award in Pharmaceutical Science and Research Award (2014), and served as Chair of American Society of Pharmacology and Experimental Therapeutics Division of Drug Metabolism (2015). In addition to consulting, he serves as an Affiliate Faculty in the Department of Medicinal Chemistry at the University of Washington and to date has published over 100 peer-reviewed manuscripts and book chapters.
Book Information
ISBN 9780128171349
Author Kan He
Format Paperback
Page Count 446
Imprint Academic Press Inc
Publisher Elsevier Science Publishing Co Inc
Weight(grams) 1250g
About the Author
Dr. Kan He holds more than 10 U.S. and international patents on new chemical entities and biotechnologies and is the author of more than 60 published scientific papers. In addition to contributing to the discovery and development of numerous successful prescription drugs currently on the market, as well as multiple preclinical and clinical development candidates, Dr. He made significant contributions to the discovery and development of the oral anticoagulant Eliquis (R) (Apixaban). Dr. He cofounded and currently serves as the General Manager of the innovative biotech service company Biotranex, now a wholly owned subsidiary of Frontage Laboratories, Inc. Dr. He has also held numerous scientific and managerial positions at Bristol-Myers Squib, Dupont Pharmaceuticals, and Pfizer, and cofounded and served as President of Princeton Drug Discovery Inc, Eternity Bioscience, and UniTris Biopharma. Dr. Paul Hollenberg is a Professor Emeritus of Pharmacology at the University of Michigan Medical School. He was on the faculty at Northwestern University Medical School, Wayne State University School of Medicine (Chair of Pharmacology), and then at the University of Michigan Medical School where he was Chair for more than 20 years. He cofounded Chemical Research in Toxicology in 1988 and has served as an Associate Editor and then Review Editor since that time. He was elected a Fellow of the American Chemical Society (2010), the American Association for the Advancement of Science (2012), and the American Society of Pharmacology and Therapeutics (2019). He has received several awards including the Scientific Achievement Award from the International Society for the Study of Xenobiotics in 2011 and the Founders Award from the Division of Chemical Toxicology of the American Chemical Society in 2014. He has published more than 200 peer-reviewed papers and received more than $29 million in NIH funding as a PI or Co-PI. Dr. Wienkers is currently the Principal Scientist of Wienkers Consulting, LLC. Prior to this, Larry was Vice President and Global Head of the department of Pharmacokinetics and Drug Metabolism at Amgen retiring in 2018. Before moving to Amgen, Dr. Wienkers held scientific and leadership positions in several companies (Upjohn, Pharmacia, and Pfizer) and worked across multiple drug modalities, resulting in clinical and preclinical candidates, with 30+ IND submissions and 10+ NDA submissions. He is an American Association of Pharmaceutical Scientists (AAPS) Fellow (2012), was the recipient of the University of Washington, School of Pharmacy Distinguished Alumni Award in Pharmaceutical Science and Research Award (2014), and served as Chair of American Society of Pharmacology and Experimental Therapeutics Division of Drug Metabolism (2015). In addition to consulting, he serves as an Affiliate Faculty in the Department of Medicinal Chemistry at the University of Washington and to date has published over 100 peer-reviewed manuscripts and book chapters.
Book Information
ISBN 9780128171349
Author Kan He
Format Paperback
Page Count 446
Imprint Academic Press Inc
Publisher Elsevier Science Publishing Co Inc
Weight(grams) 1250g
